Pfizer: FDA approves rare blood cancer treatment.
(CercleFinance.com) - The US Food and Drug Administration on Thursday approved a drug developed by Pfizer to treat a rare blood cancer that may be fatal within a matter of months.
The drug, Besponsa, chemically known as "inotuzumab ozogamicin", is designed to treat adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
The product was reviewed and approved under the FDA's breakthrough therapy designation and priority review programs.
Copyright (c) 2017 CercleFinance.com. All rights reserved.